Drugs / targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06499025 | Feb 2024 → Dec 2026 expected | acute myeloid leukemia with t(8;21)(q22;q22) translocation | BGI, China | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | targeted AML1-ETO neoantigen cytotoxic T cells (CTL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06499025 ↗ |
| Modality | Cell therapy | “targeted AML1-ETO neoantigen cytotoxic T cells (CTL)” NCT06499025 ↗ |
| Route | Other | “neoantigen cytotoxic T cells transfusion” NCT06499025 ↗ |